Abstract:Short-acting b2-adrenergic receptor agonists are commonly used bronchodilators for symptom relief in asthmatics. The aim of this study was to test whether genetic variants in PDE4D gene, a key regulator of b2-adrenoceptor-induced cAMP turnover in airway smooth muscle cells, affect the response to short-acting b2-agonists. Bronchodilator responsiveness was assessed in 133 asthmatic children by % change in baseline forced expiratory volume in one second (FEV 1 ) after administration of albuterol. The analyses were performed in patients with airway obstruction (FEV 1 /FVC ratio below 90%, n = 93 ). FEV 1 % change adjusted for baseline FEV 1 values was significantly different between genotypes of rs1544791 G/A polymorphism ( P = 0.006 ) and −1345 C/T (rs1504982) promoter variation ( P = 0.03 ). The association remained significant with inclusion of age, sex, atopy, and controller medication into multivariate model ( P = 0.004 and P = 0.02 , resp.). Our work identifies new genetic variants implicated in modulation of asthma treatment, one of them (rs1544791) previously associated with asthma phenotype.

Phosphodiesterase Type 4D Gene Polymorphism: Association with the Response to Short-Acting Bronchodilators in Paediatric Asthma Patients